(16546095), Y. B., (16546098), J. H., (16546101), X. D., (16546104), Y. W., (16546107), S. W., (16546110), W. G., . . . (16546122), P. S. (2025). Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma.
Cita Chicago Style (17a ed.)(16546095), Yuncheng Bei, et al. Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. 2025.
Cita MLA (9a ed.)(16546095), Yuncheng Bei, et al. Supplementary Table 2 from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate Is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. 2025.
Precaución: Estas citas no son 100% exactas.